Advertisement

Ultraviolet Therapy of Atopic Eczema

  • J. Krutman
  • M. Grewe
Conference paper

Abstract

Recent results from a pilot study have suggested that irradiation of patients with high doses of ultraviolet A1 radiation (UVA-1; 340–400 nm) may be effectively used as a monotherapy in the management of severe exacerbation of atopic dermatitis [1]. This assumption has recently been confirmed in a multicenter trial [2]. Accordingly, in this three-branched, randomized trial, atopic dermatitis patients were treated either with high-dose UVAi (10 days, 130 J/cm2/day; n = 20), or topically with fluocortolon (10 days, 1X daily; n = 17), or with conventional UVA-UVB therapy (10 days, 1 x daily, minimal effective dose-dependent; n = 16). By employing an established clinical scoring system, significant differences in favor of high-dose UVAi as well as fluocortolon therapy were observed (p<0.0001), as compared to UVA-UVB therapy. After 10 days, high-dose UVAi was found to be superior to fluocortolon (p<o.oo2). These clinical changes were reflected by concomitant changes in laboratory parameters. a sinificant reduction of elevated serum levels of eosinophilic cationic protein as well as of the blood eosinophil count was observed in patients undergoing high-dose UVA1 irradiation or fluocortolon treatment, but not UVA-UVB theraphy. These studies confirm the therapeutic effectiveness of high-dose UVA1 irradiation in the management of patients with atopic dermatis.

Keywords

Atopic Dermatitis Eosinophilic Cationic Protein Atopic Dermatitis Patient Blood Eosinophil Count Atopy Patch Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Krutmann J, Czech W, Diepgen T, Niedner R, Kapp A, Schöpf E: High-dose-UVAl therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 26: 225–230, 1992PubMedCrossRefGoogle Scholar
  2. 2.
    Krutmann J, Diepgen TL, Luger TA, Grabbe S, Meffert H, Soennichsen N, Czech W, Kapp A, Stege H, Grewe M, Schöpf E: High-dose-UVAl therapy for atopic dermatitis. J Invest Dermatol 104: 564, 1995Google Scholar
  3. 3.
    Grewe M, Gyufko K, Schöpf E, Krutmann J: Lesionai expression of interferon-y in atopic eczema. Lancet 343: 25–26, 1994PubMedCrossRefGoogle Scholar
  4. 4.
    Grewe M, Gyufko K, Krutmann J: Human keratinocytes produce interleukin-10: Modulation by ultraviolet B and ultraviolet Al radiation. J Invest Dermatol 104: 3–6, 1995PubMedCrossRefGoogle Scholar
  5. 5.
    Grewe M, Walter S, Gyufko K, Czech W, Schöpf E, Krutmann J: Analysis of the cytokine pattern expressed in-situ in inhalant allergen patch test reactions of atopic dermatitis patients. J Invest Dermatol 105: 407–410, 1995PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • J. Krutman
  • M. Grewe

There are no affiliations available

Personalised recommendations